Neurotrophic factors and antidepressant action: Recent advances

Modern Trends in Pharmacopsychiatry

Volumn 27, Issue , 2010, Pages 199-223

  O'Leary, Olivia F ^a   Castrén, Eero ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARTEMIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CILIARY NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; MONOAMINE OXIDASE INHIBITOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; NEUROTROPHIN RECEPTOR P75; NEURTURIN; NORADRENALIN UPTAKE INHIBITOR; PERSEPHIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRICYCLIC ANTIDEPRESSANT AGENT; VASCULOTROPIN;

BEHAVIOR CHANGE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC STRESS; DEPRESSION; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; ELECTROSTIMULATION; ENZYME ACTIVATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HIPPOCAMPUS; HUMAN; NERVE CELL; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DEPRIVATION; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 78649671050     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000319514     Document Type: Review

References (187)

1. Cheng Y, Black IB, DiCicco-Bloom E: Hippocampal granule neuron production and population size are regulated by levels of bFGF. Eur J Neurosci 2002;15:3-12.
2. Bergami M, Rimondini R, Santi S, Blum R, Gotz M, Canossa M: Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci USA 2008;105:15570-15575.
3. Thoenen H: Neurotrophins and neuronal plasticity. Science 1995;270:593-598.
4. Shimazu K, Zhao M, Sakata K, Akbarian S, Bates B, Jaenisch R, Lu B: NT-3 facilitates hippocampal plasticity and learning and memory by regulating neurogenesis. Learn Mem 2006;13:307-315.
5. Warner-Schmidt JL, Duman RS: VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 2008;8:14-19.
6. Sheline YI: Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 2003;54:338-352.
7. Pittenger C, Duman RS: Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008;33:88-109.
8. Sheline YI, Gado MH, Kraemer HC: Untreated depression and hippocampal volume loss. Am J Psychiatry 2003;160:1516-1518.
9. Lewin GR, Barde YA: Physiology of the neurotrophins. Annu Rev Neurosci 1996;19:289-317.
10. Huang EJ, Reichardt LF: Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001;24:677-736.
11. Lu B, Pang PT, Woo NH: The yin and yang of neurotrophin action. Nat Rev Neurosci 2005;6:603-614.
12. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G: Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005;57:1068-1072.
13. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70-75. (Pubitemid 36776725)
14. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P, Shelton RC: Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2009;43:247-254.
15. Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527-532.
16. Brunoni AR, Lopes M, Fregni F: A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11:1169-1180.
17. Lee HY, Kim YK: Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology 2008;57:194-199.
18. Okamoto T, Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Inoue Y, Ueda N, Nakamura J: Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1185-1190.
19. Gorgulu Y, Caliyurt O: Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. Brain Res Bull 2009;80:158-162.
20. Zanardini R, Gazzoli A, Ventriglia M, Perez J, Bignotti S, Rossini PM, Gennarelli M, Bocchio-Chiavetto L: Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord 2006;91:83-86. (Pubitemid 43254643)
21. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S: Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005;255:381-386.
22. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT: Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260-265.
23. Kang R, Chang H, Wong M, Choi M, Park J, Lee H, Jung I, Joe S, Kim L, Kim S, Kim Y, Han C, Ham B, Ko Y, Lee M: Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol 2009, E-pub ahead of print.
24. Zou YF, Wang Y, Liu P, Feng XL, Wang BY, Zang TH, Yu X, Wei J, Liu ZC, Liu Y, Tao M, Li HC, Li KQ, Hu J, Li M, Zhang KR, Ye DQ, Xu XP: Association of brain-derived neurotrophic factor genetic val66met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology 2010;61:71-78.
25. Liu X, Xu Y, Jiang S, Cui D, Qian Y, Jiang K: Familybased association study between brain-derived neurotrophic factor gene and major depressive disorder of Chinese descent. Psychiatry Res 2009;169:169-172.
26. Domschke K, Lawford B, Laje G, Berger K, Young R, Morris P, Deckert J, Arolt V, McMahon FJ, Baune BT: Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol 2010;13:93-101.
27. Tsai SJ, Cheng CY, Yu Y W, Chen TJ, Hong CJ: Association study of a brain-derived neurotrophicfactor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 2003;123 B: 19-22.
28. Verhagen M, van der Meij A, van Deurzen PA, Janzing JG, Arias-Vasquez A, Buitelaar JK, Franke B: Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 2010;15:260-271.
29. Haenisch B, Bilkei-Gorzo A, Caron MG, Bonisch H: Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression. J Neurochem 2009;111:403-416.
30. Russo-Neustadt A, Ha T, Ramirez R, Kesslak JP: Physical activity-antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. Behav Brain Res 2001;120:87-95.
31. Alfonso J, Frick LR, Silberman DM, Palumbo ML, Genaro AM, Frasch AC: Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. Biol Psychiatry 2006;59:244-251.
32. Duric V, McCarson KE: Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience 2005;133:999-1006.
33. Nibuya M, Morinobu S, Duman RS: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995;15:7539-7547.
34. Smith MA, Makino S, Kvetnansky R, Post RM: Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mrnas in the hippocampus. J Neurosci 1995;15:1768-1777.
35. MacQueen GM, Ramakrishnan K, Ratnasingan R, Chen B, Young LT: Desipramine treatment reduces the long-term behavioural and neurochemical sequelae of early-life maternal separation. Int J Neuropsychopharmacol 2003;6:391-396.
36. Bravo JA, Diaz-Veliz G, Mora S, Ulloa JL, Berthoud VM, Morales P, Arancibia S, Fiedler JL: Desipramine prevents stress-induced changes in depressive-like behavior and hippocampal markers of neuroprotection. Behav Pharmacol 2009;20:273-285.
37. Xu H, Luo C, Richardson JS, Li XM: Recovery of hippocampal cell proliferation and BDNF levels, both of which are reduced by repeated restraint stress, is accelerated by chronic venlafaxine. Pharmacogenomics J 2004;4:322-331.
38. Gersner R, Toth E, Isserles M, Zangen A: Sitespecific antidepressant effects of repeated subconvulsive electrical stimulation: potential role of brain-derived neurotrophic factor. Biol Psychiatry 2010;67:125-132.
39. Paizanis E, Renoir T, Lelievre V, Saurini F, Melfort M, Gabriel C, Barden N, Mocaer E, Hamon M, Lanfumey L: Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptorimpaired mice. Int J Neuropsychopharmacol 2010;13:759-774.
40. Dwivedi Y, Rizavi HS, Pandey GN: Antidepressants reverse corticosterone-mediated decrease in brainderived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone. Neuroscience 2006;139:1017-1029.
41. Xu H, Chen Z, He J, Haimanot S, Li X, Dyck L, Li XM: Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stressinduced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 2006;16:551-559.
42. Scaccianoce S, Del Bianco P, Paolone G, Caprioli D, Modafferi AM, Nencini P, Badiani A: Social isolation selectively reduces hippocampal brain-derived neurotrophic factor without altering plasma corticosterone. Behav Brain Res 2006;168:323-325.
43. Gourley SL, Kiraly DD, Howell JL, Olausson P, Taylor JR: Acute hippocampal brain-derived neurotrophic factor restores motivational and forced swim performance after corticosterone. Biol Psychiatry 2008;64:884-890.
44. Xu H, Steven Richardson J, Li XM: Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 2003;28:53-62.
45. Jacobsen J P, Mork A: The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 2004;1024:183-192.
46. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM: Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003;54:703-709.
47. Molteni R, Calabrese F, Bedogni F, Tongiorgi E, Fumagalli F, Racagni G, Riva MA: Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Int J Neuropsychopharmacol 2006;9:307-317.
48. Czubak A, Nowakowska E, Kus K, Burda K, Metelska J, Baer-Dubowska W, Cichocki M: Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Rep 2009;61:1017-1023.
49. Martinez-Turrillas R, Del Rio J, Frechilla D: Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. Neuropharmacology 2005;49:1178-1188.
50. Arunrut T, Alejandre H, Chen M, Cha J, Russo-Neustadt A: Differential behavioral and neurochemical effects of exercise, reboxetine and citalopram with the forced swim test. Life Sci 2009;84:584-589.
51. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I: Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 2008;1211:37-43.
52. Li B, Suemaru K, Cui R, Araki H: Repeated electroconvulsive stimuli have long-lasting effects on hippocampal BDNF and decrease immobility time in the rat forced swim test. Life Sci 2007;80:1539-1543.
53. Larsen MH, Hay-Schmidt A, Ronn LC, Mikkelsen JD: Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants. Eur J Pharmacol 2008;578:114-122.
54. Rogoz Z, Skuza G, Legutko B: Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 2005;56:661-671.
55. Muller MB, Toschi N, Kresse AE, Post A, Keck ME: Long-term repetitive transcranial magnetic stimulation increases the expression of brain-derived neurotrophic factor and cholecystokinin mRNA, but not neuropeptide tyrosine mRNA in specific areas of rat brain. Neuropsychopharmacology 2000;23:205-215.
56. Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, Gabriel C, Millan MJ, Mocaer E, Daszuta A: Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009;34:2390-2403.
57. Biggio F, Gorini G, Utzeri C, Olla P, Marrosu F, Mocchetti I, Follesa P: Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus. Int J Neuropsychopharmacol 2009;12:1209-1221.
58. Cooke JD, Grover LM, Spangler PR: Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. Neuroscience 2009;162:1411-1419.
59. Schulte-Herbruggen O, Fuchs E, Abumaria N, Ziegler A, Danker-Hopfe H, Hiemke C, Hellweg R: Effects of escitalopram on the regulation of brainderived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. J Neurosci Res 2009;87:2551-2560.
60. Calabrese F, Molteni R, Maj PF, Cattaneo A, Gennarelli M, Racagni G, Riva MA: Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 2007;32:2351-2359.
61. Reagan LP, Hendry RM, Reznikov LR, Piroli GG, Wood GE, McEwen BS, Grillo CA: Tianeptine increases brain-derived neurotrophic factor expression in the rat amygdala. Eur J Pharmacol 2007;565:68-75.
62. Coppell AL, Pei Q, Zetterstrom TS: Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003;44:903-910. (Pubitemid 36515026)
63. Mannari C, Origlia N, Scatena A, Del Debbio A, Catena M, Dell'Agnello G, Barraco A, Giovannini L, Dell'osso L, Domenici L, Piccinni A: BDNF level in the rat prefrontal cortex increases following chronic but not acute treatment with duloxetine, a dual acting inhibitor of noradrenaline and serotonin reuptake. Cell Mol Neurobiol 2008;28:457-468.
64. De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, Murray TK, Gaillard JP, Deville C, Xhenseval V, Thomas CE, O'Neill MJ, Zetterstrom TS: Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 2004;128:597-604.
65. Balu DT, Hodes GE, Anderson BT, Lucki I: Enhanced sensitivity of the MRL/MpJ mouse to the neuroplastic and behavioral effects of chronic antidepressant treatments. Neuropsychopharmacology 2009;34:1764-1773.
66. Musazzi L, Cattaneo A, Tardito D, Barbon A, Gennarelli M, Barlati S, Racagni G, Popoli M: Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. BMC Neurosci 2009;10:48.
67. Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M, Persson H: Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 1993;10:475-489.
68. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T: Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res 2007;85:525-535.
69. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T: Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007;90:397-406.
70. Pattabiraman P P, Tropea D, Chiaruttini C, Tongiorgi E, Cattaneo A, Domenici L: Neuronal activity regulates the developmental expression and subcellular localization of cortical BDNF mRNA isoforms in vivo. Mol Cell Neurosci 2005;28:556-570.
71. Khundakar AA, Zetterstrom TS: Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation. Brain Res 2006;1106:12-20.
72. Dias BG, Banerjee SB, Duman RS, Vaidya VA: Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003;45:553-563.
73. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006;9:519-525.
74. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggia LM, Self DW, Nestler EJ: Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006;311:864-868.
75. Rantamaki T, Hendolin P, Kankaanpaa A, Mijatovic J, Piepponen P, Domenici E, Chao M V, Mannisto P T, Castren E: Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 2007;32:2152-2162.
76. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, Agerman K, Haapasalo A, Nawa H, Aloyz R, Ernfors P, Castren E: Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003;23:349-357.
77. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM: Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997;56:131-137.
78. Hoshaw BA, Malberg JE, Lucki I: Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005;1037:204-208.
79. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS: Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002;22:3251-3261.
80. Sirianni RW, Olausson P, Chiu AS, Taylor JR, Saltzman WM: The behavioral and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats. Brain Res 2010;1321:40-50.
81. Govindarajan A, Rao BS, Nair D, Trinh M, Mawjee N, Tonegawa S, Chattarji S: Transgenic brainderived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci USA 2006;103:13208-13213.
82. Koponen E, Rantamaki T, Voikar V, Saarelainen T, MacDonald E, Castren E: Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell Mol Neurobiol 2005;25:973-980.
83. MacQueen GM, Ramakrishnan K, Croll SD, Siuciak JA, Yu G, Young LT, Fahnestock M: Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression. Behav Neurosci 2001;115:1145-1153.
84. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S, Parada LF, Nestler EJ: Brainderived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 2007;61:187-197.
85. Taliaz D, Stall N, Dar DE, Zangen A: Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry 2010;15:80-92.
86. Eisch AJ, Bolanos CA, de Wit J, Simonak RD, Pudiak CM, Barrot M, Verhaagen J, Nestler EJ: Brainderived neurotrophic factor in the ventral midbrainnucleus accumbens pathway: a role in depression. Biol Psychiatry 2003;54:994-1005.
87. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, Meuth S, Nagy A, Greene RW, Nestler EJ: Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004;101:10827-10832.
88. Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM: Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008;63:642-649.
89. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, Hempstead BL, Lee FS: Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006;314:140-143.
90. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809.
91. Sairanen M, Lucas G, Ernfors P, Castren M, Castren E: Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 2005;25:1089-1094.
92. Li Y, Luikart BW, Birnbaum S, Chen J, Kwon CH, Kernie SG, Bassel-Duby R, Parada LF: TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 2008;59:399-412.
93. O'Leary OF, Wu X, Castren E: Chronic fluoxetine treatment increases expression of synaptic proteins in the hippocampus of the ovariectomized rat: role of BDNF signalling. Psychoneuroendocrinology 2009;34:367-381.
94. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, Castren E, Maffei L: The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008;320:385-388.
95. Castren E: Is mood chemistry? Nat Rev Neurosci 2005;6:241-246.
96. Levi-Montalcini R: The nerve growth factor 35 years later. Science 1987;237:1154-1162.
97. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A: Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996;19:514-520.
98. Alfonso J, Pollevick GD, Van der Hart MG, Flugge G, Fuchs E, Frasch AC: Identification of genes regulated by chronic psychosocial stress and antidepressant treatment in the hippocampus. Eur J Neurosci 2004;19:659-666.
99. von Richthofen S, Lang UE, Hellweg R: Effects of different kinds of acute stress on nerve growth factor content in rat brain. Brain Res 2003;987:207-213.
100. Schulte-Herbruggen O, Chourbaji S, Muller H, Danker-Hopfe H, Brandwein C, Gass P, Hellweg R: Differential regulation of nerve growth factor and brain-derived neurotrophic factor in a mouse model of learned helplessness. Exp Neurol 2006;202:404-409.
101. Song C, Zhang XY, Manku M: Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci 2009;29:14-22.
102. Angelucci F, Aloe L, Vasquez PJ, Mathe AA: Mapping the differences in the brain concentration of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in an animal model of depression. Neuroreport 2000;11:1369-1373.
103. Overstreet DH, Fredericks K, Knapp D, Breese G, McMichael J: Nerve growth factor (NGF) has novel antidepressant-like properties in rats. Pharmacol Biochem Behav 2010;94:553-560.
104. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, Danker-Hopfe H, Gass P: Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009;42:270-276.
105. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA: Electroconvulsive stimuli alter nerve growth factor but not brain-derived neurotrophic factor concentrations in brains of a rat model of depression. Neuropeptides 2003;37:51-56. (Pubitemid 36384658)
106. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA: Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 2003;6:225-231. (Pubitemid 37248000)
107. Hellweg R, Ziegenhorn A, Heuser I, Deuschle M: Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 2008;41:66-71.
108. Hadjiconstantinou M, McGuire L, Duchemin AM, Laskowski B, Kiecolt-Glaser J, Glaser R: Changes in plasma nerve growth factor levels in older adults associated with chronic stress. J Neuroimmunol 2001;116:102-106.
109. Dwivedi Y, Mondal AC, Rizavi HS, Conley RR: Suicide brain is associated with decreased expression of neurotrophins. Biol Psychiatry 2005;58:315-324.
110. Tessarollo L, Vogel KS, Palko ME, Reid S W, Parada LF: Targeted mutation in the neurotrophin-3 gene results in loss of muscle sensory neurons. Proc Natl Acad Sci USA 1994;91:11844-11848.
111. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD: Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 1990;247:1446-1451.
112. Klein R, Silos-Santiago I, Smeyne RJ, Lira SA, Brambilla R, Bryant S, Zhang L, Snider WD, Barbacid M: Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements. Nature 1994;368:249-251.
113. Hohn A, Leibrock J, Bailey K, Barde YA: Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. Nature 1990;344:339-341.
114. Kuroda Y, McEwen BS: Effect of chronic restraint stress and tianeptine on growth factors, growthassociated protein-43 and microtubule-associated protein 2 mRNA expression in the rat hippocampus. Brain Res Mol Brain Res 1998;59:35-39.
115. Walz JC, Frey BN, Andreazza AC, Cereser KM, Cacilhas AA, Valvassori SS, Quevedo J, Kapczinski F: Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. J Psychiatr Res 2008;42:416-421.
116. Chen JX, Li W, Zhao X, Yang JX: Effects of the Chinese traditional prescription xiaoyaosan decoction on chronic immobilization stress-induced changes in behavior and brain BDNF, TrκB, and NT-3 in rats. Cell Mol Neurobiol 2008;28:745-755.
117. Smith MA, Makino S, Kvetnansky R, Post RM: Effects of stress on neurotrophic factor expression in the rat brain. Ann NY Acad Sci 1995;771:234-239.
118. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R: Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005;136:29-37.
119. Otsuki K, Uchida S, Watanuki T, Wakabayashi Y, Fujimoto M, Matsubara T, Funato H, Watanabe Y: Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res 2008;42:1145-1153.
120. Hock C, Heese K, Muller-Spahn F, Huber P, Riesen W, Nitsch RM, Otten U: Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Mol Psychiatry 2000;5:510-513.
121. Feng Y, Vetro A, Kiss E, Kapornai K, Daroczi G, Mayer L, Tamas Z, Baji I, Gadoros J, King N, Kennedy JL, Wigg K, Kovacs M, Barr CL: Association of the neurotrophic tyrosine kinase receptor 3 (NTRK3) gene and childhood-onset mood disorders. Am J Psychiatry 2008;165:610-616.
122. Teng KK, Hempstead BL: Neurotrophins and their receptors: signaling trios in complex biological systems. Cell Mol Life Sci 2004;61:35-48.
123. Walz JC, Magalhaes P V, Giglio LM, Cunha AB, Stertz L, Fries GR, Andreazza AC, Kapczinski F: Increased serum neurotrophin-4/5 levels in bipolar disorder. J Psychiatr Res 2009;43:721-723.
124. Turner CA, Akil H, Watson SJ, Evans SJ: The fibroblast growth factor system and mood disorders. Biol Psychiatry 2006;59:1128-1135.
125. Ohkubo Y, Uchida AO, Shin D, Partanen J, Vaccarino FM: Fibroblast growth factor receptor 1 is required for the proliferation of hippocampal progenitor cells and for hippocampal growth in mouse. J Neurosci 2004;24:6057-6069.
126. Bachis A, Mallei A, Cruz MI, Wellstein A, Mocchetti I: Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology 2008;55:1114-1120.
127. Maragnoli ME, Fumagalli F, Gennarelli M, Racagni G, Riva MA: Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry 2004;55:1095-1102.
128. Follesa P, Biggio F, Gorini G, Caria S, Talani G, Dazzi L, Puligheddu M, Marrosu F, Biggio G: Vagus nerve stimulation increases norepinephrine concentration and the gene expression of BDNF and bFGF in the rat brain. Brain Res 2007;1179:28-34.
129. Mallei A, Shi B, Mocchetti I: Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol 2002;61:1017-1024.
130. Turner CA, Gula EL, Taylor L P, Watson SJ, Akil H: Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res 2008;1224:63-68.
131. Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M: Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull 2006;70:221-227.
132. Evans SJ, Choudary P V, Neal CR, Li JZ, Vawter M P, Tomita H, Lopez JF, Thompson RC, Meng F, Stead JD, Walsh DM, Myers RM, Bunney WE, Watson SJ, Jones EG, Akil H: Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 2004;101:15506-15511.
133. Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L, Schweiger U: Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 2009;34:353-357.
134. Kato M, Okugawa G, Wakeno M, Takekita Y, Nonen S, Tetsuo S, Nishida K, Azuma J, Kinoshita T, Serretti A: Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. Eur Neuropsychopharmacol 2009;19:718-725.
135. Reinhardt RR, Bondy CA: Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994;135:1753-1761.
136. Werther GA, Abate M, Hogg A, Cheesman H, Oldfield B, Hards D, Hudson P, Power B, Freed K, Herington AC: Localization of insulin-like growth factor-I mRNA in rat brain by in situ hybridization - Relationship to IGF-I receptors. Mol Endocrinol 1990;4:773-778.
137. O'Kusky JR, Ye P, D'Ercole AJ: Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J Neurosci 2000;20:8435-8442.
138. Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S: Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 2007;32:2360-2368.
139. Duman CH, Schlesinger L, Terwilliger R, Russell DS, Newton SS, Duman RS: Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 2009;198:366-371.
140. Hoshaw BA, Hill TI, Crowley JJ, Malberg JE, Khawaja X, Rosenzweig-Lipson S, Schechter LE, Lucki I: Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission. Eur J Pharmacol 2008;594:109-116.
141. Grunbaum-Novak N, Taler M, Gil-Ad I, Weizman A, Cohen H, Weizman R: Relationship between antidepressants and IGF-1 system in the brain: possible role in cognition. Eur Neuropsychopharmacol 2008;18:431-438.
142. Engesser-Cesar C, Anderson AJ, Cotman CW: Wheel running and fluoxetine antidepressant treatment have differential effects in the hippocampus and the spinal cord. Neuroscience 2007;144:1033-1044.
143. Lesch K P, Rupprecht R, Muller U, Pfuller H, Beckmann H: Insulin-like growth factor I in depressed patients and controls. Acta Psychiatr Scand 1988;78:684-688.
144. Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Korner A, Standhardt H, Gotthardt U, Schmider J, Pflaum CD, Heuser I: Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997;22:493-503.
145. Franz B, Buysse DJ, Cherry CR, Gray NS, Grochocinski VJ, Frank E, Kupfer DJ: Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J Psychiatr Res 1999;33:121-127.
146. Lesch K P, Laux G, Mueller T: Alpha 2-adrenoceptor responsivity in depression: effect of chronic treatment with moclobemide, a selective MAO-A-inhibitor, versus maprotiline. J Neural Transm Suppl 1990;32:457-461.
147. Rupprecht R, Rupprecht C, Rupprecht M, Noder M, Lesch K P, Mossner J: Effects of glucocorticoids on the regulation of the hypothalamic-pituitary- somatotropic system in depression. J Affect Disord 1989;17:9-16.
148. Weber-Hamann B, Blum WF, Kratzsch J, Gilles M, Heuser I, Deuschle M: Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009;42:23-28.
149. Dvorak HF: Discovery of vascular permeability factor (VPF). Exp Cell Res 2006;312:522-526.
150. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10.
151. Warner-Schmidt JL, Madsen TM, Duman RS: Electroconvulsive seizure restores neurogenesis and hippocampus-dependent fear memory after disruption by irradiation. Eur J Neurosci 2008;27:1485-1493.
152. Udo H, Yoshida Y, Kino T, Ohnuki K, Mizunoya W, Mukuda T, Sugiyama H: Enhanced adult neurogenesis and angiogenesis and altered affective behaviors in mice overexpressing vascular endothelial growth factor 120. J Neurosci 2008;28:14522-14536.
153. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA: Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002;99:11946-11950.
154. Warner-Schmidt JL, Duman RS: VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 2007;104:4647-4652.
155. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS: Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009;34:2459-2468.
156. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I: Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 1999;147:162-167.
157. Altar CA, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J, Bukhman Y V, Young TA, Charles V, Palfreyman MG: Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 2004;24:2667-2677.
158. Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E, Duman RS: Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci 2003;23:10841-10851.
159. Segi-Nishida E, Warner-Schmidt JL, Duman RS: Electroconvulsive seizure and VEGF increase the proliferation of neural stem-like cells in rat hippocampus. Proc Natl Acad Sci USA 2008;105:11352-11357.
160. Bergstrom A, Jayatissa MN, Mork A, Wiborg O: Stress sensitivity and resilience in the chronic mild stress rat model of depression; an in situ hybridization study. Brain Res 2008;1196:41-52.
161. Heine VM, Zareno J, Maslam S, Joels M, Lucassen PJ: Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur J Neurosci 2005;21:1304-1314.
162. Tsai SJ, Hong CJ, Liou YJ, Chen TJ, Chen ML, Hou SJ, Yen FC, Yu YW: Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder. Psychiatry Res 2009;169:113-117.
163. Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, Nakataki M, Song H, Hokoishi K, Tanabe H, Sano A, Ohmori T: Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:658-663.
164. Dome P, Teleki Z, Rihmer Z, Peter L, Dobos J, Kenessey I, Tovari J, Timar J, Paku S, Kovacs G, Dome B: Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. Mol Psychiatry 2009;14:523-531.
165. Ventriglia M, Zanardini R, Pedrini L, Placentino A, Nielsen MG, Gennarelli M, Bocchio-Chiavetto L: VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:146-149.
166. Vivien D, Ali C: Transforming growth factor-beta signalling in brain disorders. Cytokine Growth Factor Rev 2006;17:121-128.
167. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, Sanisoglu SY, Yesilova Z, Ozmenler N, Ozsahin A, Sengul A: Pro-and antiinflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007;2007:76396.
168. Myint AM, Leonard BE, Steinbusch H W, Kim YK: Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 2005;88:167-173.
169. Lee KM, Kim YK: The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006;6:1298-1304.
170. Takebayashi M, Hisaoka K, Nishida A, Tsuchioka M, Miyoshi I, Kozuru T, Hikasa S, Okamoto Y, Shinno H, Morinobu S, Yamawaki S: Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int J Neuropsychopharmacol 2006;9:607-612.
171. Airaksinen MS, Saarma M: The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-394.
172. Nestler EJ, Carlezon WA Jr: The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-1159.
173. Zhang X, Zhang Z, Xie C, Xi G, Zhou H, Zhang Y, Sha W: Effect of treatment on serum glial cell linederived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:886-890.
174. Zhang X, Zhang Z, Sha W, Xie C, Xi G, Zhou H, Zhang Y: Electroconvulsive therapy increases glial cell-line derived neurotrophic factor (GDNF) serum levels in patients with drug-resistant depression. Psychiatry Res 2009;170:273-275.
175. Hisaoka K, Nishida A, Koda T, Miyata M, Zensho H, Morinobu S, Ohta M, Yamawaki S: Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 2001;79:25-34.
176. Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, Yamawaki S: Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signalregulated kinase in glial cells. J Pharmacol Exp Ther 2007;321:148-157.
177. Chen AC, Eisch AJ, Sakai N, Takahashi M, Nestler EJ, Duman RS: Regulation of GFRalpha-1 and GFRalpha-2 mRNAs in rat brain by electroconvulsive seizure. Synapse 2001;39:42-50.
178. Michel TM, Frangou S, Camara S, Thiemeyer D, Jecel J, Tatschner T, Zoechling R, Grunblatt E: Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: a comparative post-mortem study. Eur Psychiatry 2008;23:413-420.
179. Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, Lampe PA, Heuckeroth RO, Kotzbauer PT, Simburger KS, Golden J P, Davies JA, Vejsada R, Kato AC, Hynes M, Sherman D, Nishimura M, Wang LC, Vandlen R, Moffat B, Klein RD, Poulsen K, Gray C, Garces A, Johnson EM Jr, et al: Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 1998;20:245-253.
180. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM Jr, Milbrandt J: Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 1998;21:1291-1302.
181. Chourbaji S, Urani A, Inta I, Sanchis-Segura C, Brandwein C, Zink M, Schwaninger M, Gass P: IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol Dis 2006;23:587-594.
182. Pechnick RN, Chesnokova VM, Kariagina A, Price S, Bresee CJ, Poland RE: Reduced immobility in the forced swim test in mice with a targeted deletion of the leukemia inhibitory factor (LIF) gene. Neuropsychopharmacology 2004;29:770-776.
183. Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M: Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res 2001;105:165-174.
184. Muller S, Chakrapani BP, Schwegler H, Hofmann HD, Kirsch M: Neurogenesis in the dentate gyrus depends on ciliary neurotrophic factor and signal transducer and activator of transcription 3 signaling. Stem Cells 2009;27:431-441.
185. Bloch J, Bachoud-Levi AC, Deglon N, Lefaucheur JP, Winkel L, Palfi S, Nguyen JP, Bourdet C, Gaura V, Remy P, Brugieres P, Boisse MF, Baudic S, Cesaro P, Hantraye P, Aebischer P, Peschanski M: Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004;15:968-975.
186. Gelernter J, Van Dyck C, van Kammen DP, Malison R, Price LH, Cubells JF, Berman R, Charney DS, Heninger G: Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. Am J Med Genet 1997;74:497-500.
187. Grunblatt E, Hupp E, Bambula M, Zehetmayer S, Jungwirth S, Tragl KH, Fischer P, Riederer P: Association study of BDNF and CNTF polymorphism to depression in non-demented subjects of the 'VITA' study. J Affect Disord 2006;96:111-116.